Shots:

• The alliance will leverage AbCellera's rapid pandemic response platform- developed under the DARPA P3 program with Eli Lilly’s development & manufacturing capabilities. The companies will equally share the initial development cost while Lilly will be solely responsible for further development- manufacturing & distribution activities
• The companies have identified ~500+ unique Ab isolated from one of the first US patients who recovered from COVID-19- later they screen these Ab to find the most effective Abs- neutralizing SARS-CoV-2
• Selected Abs will be expressed in collaboration with VRC at NIAID and pending agreement with NIAID will be tested Abs for their ability to neutralize the virus

Click here ­to­ read full press release/ article 

Ref: Eli Lilly  | Image: Eli Lilly